Validation of the FACT-Lym scale to measure quality of life in Colombian patients with lymphoma
Validación de la escala FACT-Lym para la evaluación de la calidad de vida en pacientes colombianos con linfoma
Palabras clave:
Quality of Life, Lymphoma, Surveys and Questionnaires, Validation Studies (en)Calidad de vida, Linfoma, Encuestas y cuestionarios, Estudios de validación (es)
Descargas
Introduction: Instruments for measuring quality of life must be validated before being used in different cultural contexts. There is a specific scale (FACT-Lym) to assess health-related quality of life (HRQOL) in patients with lymphoma, but it has not been validated in Colombia yet.
Objective: To determine the clinimetric properties of the FACT-Lym scale in Colombian patients with lymphoma.
Materials and methods: A validation study of a scale was conducted based on the classical test theory. The FACT-Lym scale was administered to 301 patients diagnosed with different types of lymphomas and treated at the National Cancer Institute of Colombia, and their sociodemographic and clinical data were recorded. The statistical analysis included exploratory factor analysis, confirmatory factor analysis, construct validity, internal consistency, test-retest reliability and sensitivity to change.
Results: The exploratory factor analysis confirmed a two-factor structure of the scale, while the confirmatory analysis showed adequate adjustment of the model. Internal consistency was measured using the Cronbach’s alpha coefficient (>0.8 on the global scale and on each of the factors). Correlation values significantly different from zero were found between the FACT-Lym scale and the FACT-G scale domains. No significant changes were observed in any domain of the FACT-Lym scale after the completion or suspension of treatment.
Conclusions: The validation of the FACT-Lym questionnaire in Colombia showed it has a consistent factorial structure and adequate reliability. However, its sensitivity to change should be verified by evaluating its performance in other patient groups.
Introducción. Los instrumentos para medir la calidad de vida se deben validar antes de ser utilizados en diferentes contextos culturales. En la actualidad existe una escala específica (FACT-Lym) para medir la calidad de vida en pacientes con linfoma, sin embargo esta no ha sido validada en Colombia.
Objetivo. Establecer las propiedades clinimétricas de la escala FACT-Lym en pacientes colombianos con linfoma.
Materiales y métodos. Se realizó un estudio de validación de escalas según la teoría clásica de test. Se aplicó la escala FACT-Lym a 301 pacientes del Instituto Nacional de Cancerología diagnosticados con diferentes tipos de linfoma y se registraron sus datos sociodemográficos y clínicos. El análisis estadístico incluyó análisis factorial exploratorio, análisis factorial confirmatorio, validez de constructo, consistencia interna, confiabilidad test re-test y sensibilidad al cambio.
Resultados. El análisis factorial exploratorio confirmó una estructura de dos factores de la escala, mientras que el análisis confirmatorio mostró un adecuado ajuste del modelo estructural. La consistencia interna se midió con el coeficiente alfa de Cronbach (>0.8 en la escala global y en cada uno de los factores). Se encontraron valores de correlación significativamente diferentes a cero entre la FACT-Lym y los dominios de la escala FACT-G. No se observaron cambios significativos en ninguno de los dominios de la FACT-Lym luego de completar o suspender el tratamiento.
Conclusiones. La validación de la escala FACT-Lym en Colombia mostró que esta tiene una estructura factorial consistente y una adecuada confiabilidad. Sin embargo, su sensibilidad al cambio debe verificarse evaluando su desempeño en otras poblaciones.
Descargas
Citas
Organización Mundial de la Salud [Internet]. Ginebra: Organización Mundial de la Salud; 2018 [cited 2020 Jun 20]. Available from: https://bit.ly/2Ykmsco.
Huh J. Epidemiologic overview of malignant lymphoma. Korean J Hematol. 2012;47(2):92-104. http://doi.org/f33977.
Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J. Lymphoma classification - from controversy to consensus: The R.E.A.L. and WHO Classification of lymphoid neoplasms. Ann Oncol. 2000;11(Suppl 1):3-10. http://doi.org/dzvm.
Morton LM, Sampson JN, Cerhan JR, Turner JJ, Vajdic CM, Wang SS, et al. Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014(48):1-14. http://doi.org/f3ph4t.
International Agency for Research on Cancer. The Global Cancer Observatory. Globocan 2018. Lyon: IARC; 2019 [cited 2020 Jul 07]. Available from: https://bit.ly/2Z6Q65k.
Fondo Colombiano de Enfermedades de Alto Costo. Cuenta de Alto Costo. Boletín de información técnica especializada. Volumen 3. Número 14. Bogotá D.C.: Fondo Colombiano de Enfermedades de Alto Costo; 2017.
Baris D, Zahm SH. Epidemiology of lymphomas. Curr Opin Oncol. 2000;12(5):383-94. http://doi.org/bhrwfq.
Shah RV, Murthy VL, Allison MA, Ding J, Budoff M, Frazier-Wood AC, et al. Diet and adipose tissue distributions: The Multi-Ethnic Study of Atherosclerosis. Nutr Metab Cardiovasc Dis. 2016;26(3):185-93. http://doi.org/f8c4mh.
American Cancer Society [Internet]. New York: American Cancer Society; 2019 [cited 2020 Jun 20]. Available from: https://bit.ly/2Ngizis.
Hoppe RT, Mauch PT, Armitage JO, Diehl V, Weiss LM. Hodgkin Lymphoma. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2007.
Bilodeau BA, Fessele KL. Non-Hodgkin's lymphoma. Semin Oncol Nurs. 1998;14(4):273-83. http://doi.org/fqrjsj.
Hale GA, Phillips GL. Allogeneic stem cell transplantation for the non-Hodgkin's lymphomas and Hodgkin's disease. Cancer Treat Rev. 2000;26(6):411-27. http://doi.org/drs9bw.
Duvic M, Kuzel TM, Olsen EA, Martin AG, Foss FM, Kim YH, et al. Quality-of-life Improvements in Cutaneous T-cell Lymphoma Patients Treated with Denileukin Diftitox (ONTAK®). Clin Lymphoma. 2002;2(4):222-8. http://doi.org/c4wfd3.
Urzúa A, Caqueo-Urízar A. Calidad de vida: Una revisión teórica del concepto. Ter Psicol. 2012;30(1):61-71. http://doi.org/dzvx.
World Health Organization. WHOQOL: Measuring Quality of Life. Ginebra: WHO; 1997 [cited 2020 Jun 20]. Available from: https://bit.ly/317foSB.
Paraskevi T. Quality of life outcomes in patients with breast cancer. Oncol Rev. 2012;6(1):e2. http://doi.org/dzvz.
American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol. 1996;14(2):671-9. http://doi.org/dzv3.
Flechtner H, Rüffer JU, Henry-Amar M, Mellink WA, Sieber M, Fermé C, et al. Quality of life assessment in Hodgkin's disease: a new comprehensive approach. First experiences from the EORTC/GELA and GHSG trials. Ann Oncol. 1998;9(Suppl 5):S147-54. http://doi.org/dzv7.
Cruz-Bermúdez HF, Moreno-Collazos JE, Angarita-Fonseca A. Medición de la calidad de vida por el cuestionario QLQ-C30 en sujetos con diversos tipos de cáncer de la ciudad de Bucaramanga-Colombia. Enferm Glob. 2013 [cited 2020 Jun 20];12(30):294-303. Available from: https://bit.ly/30XygmV.
Soares A, Biasoli I, Scheliga A, Baptista RL, Brabo EP, Morais JC, et al. Association of social network and social support with health-related quality of life and fatigue in long-term survivors of Hodgkin lymphoma. Support Care Cancer. 2013;21(8):2153-9. http://doi.org/f435j6.
Ferrell BR, Dow KH, Grant M. Measurement of the quality of life in cancer survivors. Qual Life Res. 1995;4(6):523-31. http://doi.org/b8bds7.
Smith SK, Williams CS, Zimmer CR, Zimmerman S. An Exploratory Model of the Relationships Between Cancer-Related Trauma Outcomes on Quality of Life in Non-Hodgkin Lymphoma Survivors. J Psychosoc Oncol. 2011;29(1):19-34. http://doi.org/cmt8hf.
Vilagut G, Ferrer M, Rajmil L, Rebollo P, Permanyer-Miralda G, Quintana JM, et al. El Cuestionario de Salud SF-36 español: una década de experiencia y nuevos desarrollos. Gac Sanit. 2005 [cited 2020 Jun 20];19(2):135-50. Available from: https://bit.ly/2zNAIkA.
Hlubocky FJ, Webster K, Cashy J, Beaumont J, Cella D. The Development and Validation of a Measure of Health-Related Quality of Life for Non-Hodgkin’s Lymphoma: The Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym). Lymphoma. 2013;2013:1-9. http://doi.org/gb7gqp.
Georgakopoulos A, Kontodimopoulos N, Chatziioannou S, Niakas D. EORTC QLQ-C30 and FACT-Lym for the assessment of health-related quality of life of newly diagnosed lymphoma patients undergoing chemotherapy. Eur J Oncol Nurs. 2013;17(6):849-55. http://doi.org/f2nw38.
Sánchez R, Ballesteros M, Ortiz N. Análisis de la validez de contenido de la escala FACT-G mediante técnicas de escalamiento multidimensional. Rev Colom Cancerol. 2010 [cited 2020 Jun 20];14(4):225-33. Available from: https://bit.ly/3ejZpUT.
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570-9. http://doi.org/gf3xw2.
Cella D, Chang CH, Lai JS, Webster K. Advances in quality of life measurements in oncology patients. Semin Oncol. 2002;29(3 Suppl 8):60-8. http://doi.org/cgzrhd.
MacCallum RC, Hong S. Power Analysis in Covariance Structure Modeling Using GFI and AGFI. Multivariate Behav Res. 1997;32(2):193-210. http://doi.org/ccrwr2.
Taylor R. Interpretation of the Correlation Coefficient: A Basic Review. J Diagn Med Sonogr. 1990;6(1):35-9. http://doi.org/dxz9rw.
Lin L, Hedayat AS, Wu W. Statistical Tools for Measuring Agreement. New York: Springer; 2012.
Bonett DG. Sample size requirements for estimating intraclass correlations with desired precision. Stat Med. 2002;21(9):1331-5. http://doi.org/dw6ct8.
Feldt LS, Woodruff DJ, Salih FA. Statistical Inference for Coefficient Alpha. Appl Psychol Meas. 1987;11(1):93-103. http://doi.org/dp527f.
Sánchez R, Ballesteros M, Arnold BJ. Validation of the FACT-G scale for evaluating quality of life in cancer patients in Colombia. Qual Life Res. 2011;20(1):19-29. http://doi.org/bv9qtn.
Cella D, Nowinski CJ. Measuring quality of life in chronic illness: The functional assessment of chronic illness therapy measurement system. Arch Phys Med Rehabil. 2002;83(Suppl 2):S10-7. http://doi.org/fnx64t.
García I, Sarabia L, Cruz-Ortiz M, Aldama JM. Robustness of the extraction step when parallel factor analysis (PARAFAC) is used to quantify sulfonamides in kidney by high performance liquid chromatography-diode array detection (HPLC-DAD). Analyst. 2004;129(8):766-71. http://doi.org/ddkjf3.
Trizano-Hermosilla I, Alvarado JM. Best Alternatives to Cronbach's Alpha Reliability in Realistic Conditions: Congeneric and Asymmetrical Measurements. Front Psychol. 2016;7:769. http://doi.org/gfjz27.
Pett MA, Lackey NR, Sullivan JJ. Making Sense of Factor Analysis: The Use of Factor Analysis for Instrument Development in Health Care Research. California: Sage Publishing; 2003.
Asociación Médica Mundial. Declaración de Helsinki de la Asociación Médica Mundial. Principios éticos para las investigaciones médicas en seres humanos. Fortaleza: 64.a Asamblea General de la AMM; 2013 [cited 2020 Jun 20]. Available from: https://goo.gl/hvf7l1.
Colombia. Ministerio de Salud. Resolución 8430 de 1993 (octubre 4): Por la cual se establecen las normas científicas, técnicas y administrativas para la investigación en salud. Bogotá D.C.; octubre 4 de 1993 [cited 2017 Dec 9]. Available from: https://goo.gl/agV1mY.
Departamento Administrativo Nacional de Estadística DANE. Estratificación socioeconómica para servicios públicos domiciliarios. Bogotá D.C.: DANE; 2015 [cited 2015 Dec 15]. Available from: http://bit.ly/2IUai29.
Licencia
Derechos de autor 2020 Revista de la Facultad de Medicina

Esta obra está bajo una licencia Creative Commons Reconocimiento 3.0 Unported.
-